GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Valuation Rank

Sagimet Biosciences (STU:0O2) Valuation Rank


View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sagimet Biosciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Valuation Rank
Comparable Companies
TIL PROK TELO ENTA GNLX ELTX CCCC RGLS MCRB CSBR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
SGMT:USA 0O2:Germany
Address
155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Website
https://www.sagimet.com
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.